Parker Institute for Cancer Immunotherapy
Kevin Marks serves as General Counsel at PICI, where he oversees Legal, Intellectual Property and Human Resources.
Before joining PICI, Marks was General Counsel at the California Institute for Regenerative Medicine (CIRM), where he was responsible for Legal, Human Resources, Grants Management and IT. Marks joined CIRM in 2021 after 14 years at Roche Diagnostics in the therapeutics and diagnostics areas, serving as Vice President and Head of Legal and Compliance at Roche Molecular Solutions (encompassing molecular diagnostics, tissue diagnostics and sequencing) and Vice President and General Counsel at Roche Molecular Diagnostics. In these roles, Marks oversaw teams in general law, employment law, compliance and intellectual property. He also managed the business area’s global litigation portfolio, coordinated legal and compliance support for nine U.S. states, as well as in Europe and Africa, and directed the acquisition and legal integration of six startup companies. Prior to that, Marks served in Roche’s pharmaceutical side for nine years as Vice President, General Counsel at Roche Palo Alto, LLC.
He earned his undergraduate AB degree in International Affairs and Russian at Lafayette College and his law degree at Villanova University.
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.